227 related articles for article (PubMed ID: 31905429)
1. Treatment of Isoniazid-Resistant Pulmonary Tuberculosis.
Jhun BW; Koh WJ
Tuberc Respir Dis (Seoul); 2020 Jan; 83(1):20-30. PubMed ID: 31905429
[TBL] [Abstract][Full Text] [Related]
2. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan.
Khan MT; Malik SI; Ali S; Sheed Khan A; Nadeem T; Zeb MT; Masood N; Afzal MT
Microb Drug Resist; 2018 Nov; 24(9):1417-1421. PubMed ID: 29584579
[TBL] [Abstract][Full Text] [Related]
4. Increasing drug resistance of Mycobacterium tuberculosis isolates in a medical center in northern Taiwan.
Su WJ; Feng JY; Huang CC; Perng RP
J Formos Med Assoc; 2008 Mar; 107(3):259-64. PubMed ID: 18400612
[TBL] [Abstract][Full Text] [Related]
5. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE
Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.
Cornejo Garcia JG; Alarcón Guizado VA; Mendoza Ticona A; Alarcon E; Heldal E; Moore DAJ
PLoS One; 2018; 13(12):e0206658. PubMed ID: 30513085
[TBL] [Abstract][Full Text] [Related]
7. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
Justine M; Yeconia A; Nicodemu I; Augustino D; Gratz J; Mduma E; Heysell SK; Kivuyo S; Mfinanga S; Peloquin CA; Zagurski T; Kibiki GS; Mmbaga B; Houpt ER; Thomas TA
J Pediatric Infect Dis Soc; 2020 Feb; 9(1):14-20. PubMed ID: 30395239
[TBL] [Abstract][Full Text] [Related]
9. Mycobacterium tuberculosis resistance pattern against first-line drugs in patients from urban area.
Cucunawangsih ; Wiwing V; Widysanto A; Lugito NP
Int J Mycobacteriol; 2015 Dec; 4(4):302-5. PubMed ID: 26964812
[TBL] [Abstract][Full Text] [Related]
10. Quinolones and multidrug-resistant tuberculosis.
Maranetra KN
Chemotherapy; 1999; 45 Suppl 2():12-8. PubMed ID: 10449893
[TBL] [Abstract][Full Text] [Related]
11. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa.
Maningi NE; Malinga LA; Antiabong JF; Lekalakala RM; Mbelle NM
BMC Infect Dis; 2017 Dec; 17(1):795. PubMed ID: 29282012
[TBL] [Abstract][Full Text] [Related]
12. Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients.
Lin HC; Yu MC; Liu HJ; Bai KJ
J Formos Med Assoc; 2014 May; 113(5):291-7. PubMed ID: 24594059
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Whole-Genome Sequence Method to Diagnose Resistance of 13 Anti-tuberculosis Drugs and Characterize Resistance Genes in Clinical Multi-Drug Resistance
Chen X; He G; Wang S; Lin S; Chen J; Zhang W
Front Microbiol; 2019; 10():1741. PubMed ID: 31417530
[No Abstract] [Full Text] [Related]
14. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
Malone RS; Fish DN; Spiegel DM; Childs JM; Peloquin CA
Am J Respir Crit Care Med; 1999 May; 159(5 Pt 1):1580-4. PubMed ID: 10228130
[TBL] [Abstract][Full Text] [Related]
15. Isoniazid resistance among rifampicin-susceptible Mycobacterium tuberculosis isolates from tuberculosis patients.
Arora J; Singhal R; Verma AK; Kumar G; Bhalla M; Sarin R; Myneedu VP
Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S127-S128. PubMed ID: 28043503
[TBL] [Abstract][Full Text] [Related]
16. Initial drug regimen for active tuberculosis cases in Montreal, 1995 to 1998.
Rivest P; Tannenbaum TN
Can J Infect Dis; 2001 Mar; 12(2):89-92. PubMed ID: 18159322
[TBL] [Abstract][Full Text] [Related]
17. The impact of isoniazid resistance on the treatment outcomes of smear positive re-treatment tuberculosis patients in the state of Andhra Pradesh, India.
Deepa D; Achanta S; Jaju J; Rao K; Samyukta R; Claassens M; Kumar AM; Ph V
PLoS One; 2013; 8(10):e76189. PubMed ID: 24146839
[TBL] [Abstract][Full Text] [Related]
18. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2008 and 2009. A report of the Australian Mycobacterium Reference Laboratory Network.
Lumb R; Bastion I; Carter R; Jelfs P; Keehner T; Sievers A
Commun Dis Intell Q Rep; 2011 Jun; 35(2):154-61. PubMed ID: 22010508
[TBL] [Abstract][Full Text] [Related]
19. The association between cytochrome P450 polymorphisms and anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis.
Liu X; Ren S; Zhang J; Xu D; Jiang F; Jiang P; Feng J; Deng F
Ann Palliat Med; 2021 Jun; 10(6):6518-6534. PubMed ID: 34154362
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
